Scottish Development International
Scottish Development International (SDI) is part of Scotland’s main enterprise, innovation and investment agency and works to help international companies find partners in Scotland and Scottish companies develop their business overseas. SDI also works to attract inward investment and knowledge to Scotland in order to help the economy grow.
SDI has a network of offices around the world and provides a wide range of support services covering each phase of international activity, including: business mentoring, market intelligence, business location information and investor aftercare.
The Scottish Life Sciences sector counts more than 700 organisations and 35,000 people with particular strengths in supporting drug discovery and development, regenerative medicine/stem cells, animal health, medical devices, digital health and clinical translational medicine.
Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.
David CarverBusiness Development
Exhibiting at booth 4
SQN Clinical is one of the largest specialist Biometrics CROs in Europe and is the preferred clinical development partner for many pharmaceutical, biotechnology and animal healthcare companies in the UK, Europe and the rest of world. We have a breadth of experience in many therapeutic areas as well as clinical development phases. Noted for our flexibility we support the diverse needs of large and small organisations alike but always provide the assurance that advice and services offered will always meet development and regulatory needs.
For a demo of the system come and see us at booth 4
Mr Shiyan CaanBusiness Development and Marketing Coordinator
Pauline AllenBusiness Support Manager
SYNthesis Research is a research “venture partner” that draws upon a deep well of experience in small molecule drug discovery, to partner with the outstanding biology of our collaborators to develop and mature new drug candidates for a broad range of therapeutic applications.
As well as developing our own pipeline of early-stage projects, SYNthesis Research has developed partnerships with the Walter and Eliza Hall Institute for Medical Research, and the Cancer Therapeutics Co-operative Research Centre (CTx-CRC), inter alia.
SYNthesis Research brings management, expertise and financing to the table, and our sister company, SYNthesis med chem, brings a chemistry-focussed contract research service to our collaborations, providing custom synthesis, medicinal chemistry and fully integrated drug discovery capabilities that delivers cost effective high quality drug discovery and development capability.
We are seeking innovation partners for shared risk, in-licensing and partnering.